Ziopharm Oncology’s Controlled IL-12 Platform Receives EMA’s COMP Positive Recommendation for Orphan Drug Designation to Treat Glioma

 Ziopharm Oncology’s Controlled IL-12 Platform Receives EMA’s COMP Positive Recommendation for Orphan Drug Designation to Treat Glioma

Ziopharm Oncology’s Controlled IL-12 Platform Receives EMA’s COMP Positive Recommendation for Orphan Drug Designation to Treat Glioma

Shots:

  • EMA’s Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending Ziopharm’s Controlled IL-12 platform (Ad-RTS-hIL-12 + veledimex) for ODD candidate for the treatment of glioma
  • EMA’s ODD provides regulatory and financial incentives to the company for developing & commercializing therapies for life-threatening diseases no more than five in 10,000 persons in EU and granting an additional 10yrs. period of marketing exclusivity in the EU post approval
  • Ziopharm’s Controlled IL-12 platform is an investigational gene therapy designed to target human interleukin 12 (hIL-12) of the immune system and has received FDA’s FT designation for the treatment of rGBM in adults

Click here to­ read full press release/ article | Ref: Ziopharm | Image: Immuno-Oncology News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post